Cristiana Lupi

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

Rossella Elisei, Clara Ugolini, David Viola et al. · The Journal of Clinical Endocrinology & Metabolism · 2008 · 527 citations

Medicine, Molecular Genetics, Oncology +16

Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma

Cristiana Lupi, Riccardo Giannini, Clara Ugolini et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 393 citations · Full text

Medicine, Oncology, Pathology +17

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Gianluca Masi, Fotios Loupakis, Lisa Salvatore et al. · The Lancet Oncology · 2010 · 240 citations

Medicine, Oncology, Pharmacology +10

The<i>BRAF</i>V600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study

Rossella Elisei, David Viola, Liborio Torregrossa et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 236 citations · Full text

Medicine, Molecular Genetics, Oncology +12